Exendin agonist compounds

Details Exendin agonist compounds Exendin agonist compounds

2007-05-29

2007-05-29

Kerr, Kathleen M. (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S308000, C530S322000

Reexamination Certificate

active

09554533

ABSTRACT:
The present invention relates to novel exendin agonist compounds useful in treatment of Type I and II diabetes, and useful in lowering plasma glucose levels, reducing body weight, and delaying and/or slowing gastric emptying.

REFERENCES:
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5424286 (1995-06-01), Eng
patent: 5512549 (1996-04-01), Chen
patent: 5545618 (1996-08-01), Buckley
patent: 5574008 (1996-11-01), Johnson
patent: 5686511 (1997-11-01), Bobo
patent: 6191102 (2001-02-01), DiMarchi et al.
patent: 6399601 (2002-06-01), Du Bois
patent: 6506724 (2003-01-01), Hiles et al.
patent: 6858576 (2005-02-01), Young et al.
patent: 6956026 (2005-10-01), Beeley et al.
patent: WO 9011296 (1990-10-01), None
patent: WO 9111457 (1991-08-01), None
patent: WO 9318786 (1993-09-01), None
patent: WO 9325579 (1993-12-01), None
patent: WO 9805351 (1998-02-01), None
patent: WO 9819698 (1998-05-01), None
patent: WO 9830231 (1998-07-01), None
patent: WO 9907404 (1999-02-01), None
Peeters et al. (1983) Proline-rich polypeptides bound to rat prostatic binding protein. The primary structure of the two main components, proline-rich polypeptides IV and V. J. Biol. Chem. 258, No. 23, 14206-14211.
Adelhorst, K., et al., “Structure-activity Studies of Glucagon-like Peptide-1 (GLP-1),”J. Biol. Chem., 269(9):6275-8 (1994).
Bartlett, et al., “Inhibition of Chymotrypsin by Phosphonate and Phosphonamidate Peptide Analogs,”Bioorg. Chem., 14:356-377 (1986).
Bhavsar, “Inhibition of Gastric Emptying and of Food Intake Appear to Be Independently Controlled in Rodents,”Soc. Neurosci. Abst., 21:460 (188.8)(1995).
Cohen, et al.,The Pico Tag Method: A Manuel of Advanced Techniques for Amino Acid Analysis, pp. 11-52, Millipore Corporation (1989).
D'Alessio, et al., “Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons,”J. Clin. Invest., 97:133-38 (1996).
Eissele, et al., “Rat Gastric Somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-Like Peptide-1 (GLP-1) Amide,”Life Sci., 55:629-34 (1994).
Eng, et al., “Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, fromHeloderma suspectumVenom,”J. Biol. Chem., 267:7402-05 (1992).
Eng, et al., “Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated fromHeloderma horridumVenom,”J. Biol. Chem., 265:20259-62 (1990).
Fehmann, et al., “Stable Expression of the Rat GLP-I Receptor in CHO Cells: Activation and Binding Characteristics Utilizing GLP-I(7-36)-Amide, Oxyntomodulin, Exendin-4, and Exendin(9-39),”Peptides, 15(3):453-6 (1994).
Ferguson, et al., “Cell-Surface Anchoring of Proteins Via Glycosyphosphatidylinositol Structures,”Annu. Rev. Biochem., 57:285-320 (1988).
Goke, et al., “Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β-Cells,”J. Biol. Chem., 268:19650-55 (1993).
Goldstone, et al., “Leptin Interacts with Glucagon-like Peptide-1 Neurons to Reduce Food Intake and Body Weight in Rodents,”FEBS Letters, 415:134-138 (1997).
Halaas, J.L., et al., “Weight-Reducing Effects of the Plasma Protein Encoded by the Obese Gene,”Science, 269:543-546 (1995).
Kodama, J., et al., “Effect of Captopril on Glucose Concentration Possible Role of Augmented Postprandial Forearm Blood Flow,”Diabetes Care, 13(11):1109-1111 (1990).
Kolligs, et al., “Reduction of the Incretin Effect in Rats by the Glucagon-like Peptide-1 Receptor Antagonist Exendin (9-39) Amide,”Diabetes, 44:16-19 (1995).
Leibel, R.L., et al., “Changes in Energy Expenditure Resulting from Altered Body Weight,”New England Journal of Medicine, 332(10):621-628 (1995).
Lithell, et al., “Insulin Sensitivity in Newly Detected Hypertensive Patients: Influence of Captopril and Other Antihypertensive Agents on Insulin Sensitivity and Related Biological Parameters,”J. Cardiovasc. Pharmacol., 15 (Supp 5):S46-S52 (1990).
Malhotra, et al., “Exendin-4, a New Peptide fromHeloderma suspectumVenom, Potentiates Cholecystokinin-induced Amylase Release from Rat Pancreatic Acini,”Regulatory Peptides, 41:149-56 (1992).
Montrose-Rafizadeh, et al., “Structure-function Analysis of Exendin-4 / GLP-1 Analogs,”Diabetes, 45 (Suppl. 2):152A (1996).
Navarro, M. et al., “Colocalization of Glucagon-Like Peptide-1 (GLP-1) Receptors, Glucose Transporter GLUT-2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP-1 Receptor Agonists as an Inhibitory Signal for Food and Water Intake,”Journal of Neurochemistry, 67:1982-1991 (1996).
Ørskov, et al., “Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable,”Diabetes, 42:658-61 (1993).
Pelleymounter, et al., “Effects of the Obese Gene Product on Body Weight Regulation in ob/ob Mice,”Science, 269:540-543 (1995).
Raufman, et al., “Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas,”J. Biol. Chem., 267:21432-37 (1992).
Raufman, et al., “Exendin-3, a Novel Peptide fromHeloderma horridumVenom, Interacts with Vasoactive Intestinal Peptide Receptors and a Newly Described Receptor on Dispersed Acini from Guinea Pig Pancreas,”J. Biol. Chem., 266:2897-902 (1991).
Schepp, et al., “Exendin-4 and exendin-(9-39)NH2: Agonist and Antagonist, Respectively, at the Rat Parietal Cell Receptor for Glucagon-like Peptide-1-(7-36)NH2,”Eur. J. Pharm., 269:183-91 (1994).
Schjoldager, et al., “GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans,”Dig. Dis. Sci., 34 (5):703-8 (1989).
Singh, et al., “Use of125I-[Y39]Exendin-4 to Characterize Exendin Receptors on Dispersed Pancreatic Acini and Gastric Chief Cells from Guinea Pig,”Regul. Pept., 53:47-59 (1994).
Thorens, “Expression Cloning of the Pancreatic B Cell Receptor for the Gluco-Incretin Hormone Glucagon-like Peptide 1,”Proc. Natl. Acad. Sci. USA, 89:8641-45 (1992).
Thorens, et al., “Cloning and Functional Expression of the Human Islet GLP-1 Receptor,”Diabetes, 42 (11):1678-82 (1993).
Turton, et al., “A Role for Glucagon-Like Peptide-1 in the Central Regulation of Feeding,”Nature, 379:69-72 (1996).
Veale, P.R., et al., The Presence of Islet Amyloid Polypeptide/Calcitonin Gen-Related Peptide/Salmon Calcitonin Binding Sites in the Rat Nucleus.
Wang, et al., “Glucagon-like Peptide-1 Is a Physiological Incretin in Rat,”J. Clin. Invest., 95:417-21 (1995).
Watson, N., et al., “Effects of Captopril on Glucose Tolerance in Elderly Patients with Congestive Cardiac Failure,”Current Medical Research and Opinion, 12(6):374-378 (1991).
Wettergren, et al., “Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man,”Dig. Dis. Sci., 38(4):665-73 (1993).
Willms, et al., “Gastric Emptying Glucose Responses, and Insulin Secretion after a Liquid Test Mel: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients,”J. Clin. Endocrinol. Metab., 81(1):327-32 (1996).
Young, et al.,Program and Abstracts, 10thInternational Congress of Endocrinology Jun. 12-15, 1996, San Francisco, p. 419 (p. 2-58).

Affiliated with

Also associated with

Rating

Exendin agonist compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Exendin agonist compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Exendin agonist compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3782885